Previously in PharmaShots Magazine, we explored Companion Animals as a theme. For the September Edition, our theme is centered on livestock animals. Livestock farming remains one of the key sectors in agrarian economies like India, China, and Latin American countries. Livestock farming provides us with milk and meat enriched with essential nutritional compounds like protein. …
Introducing the third installment of our recently launched Complimentary Exclusive Video Interview. Jonathan Usuka, Chief Business Officer at Sapient, highlighted Sapient’s high throughput proteomics and metabolomics capabilities to generate multi-omics data and the analytical power to transcend the genome to achieve robust biological discoveries in expediting clinical studies.
By leveraging Sapient's real-world data asset, the…
Shots:
An equity hedge fund manager company, BVF Partners invests in small cap and early-stage biotechnology companies
In 2023, BVF participated in five investment rounds and added 20 companies to its portfolio
For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com
Established in 1993 in San Francisco, California,…
Shots:
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients
The major highlights were the US FDA’s approval of Sandoz’s Enzeevu for Treating Neovascular Age-Related…
Shots:
With more than 50 percent of ongoing clinical trials, Oncology remains one of the most explored therapy areas in healthcare
In 2023, the global oncology market was valued at $222.36B and is envisioned to grow to $521.6B by 2033, registering a CAGR of 8.9% from 2024 to 2033. With $27.6B registered oncology revenue, Merck…
Shots:
PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 16 small molecules, 5 biologics, 11 cell & gene therapies, 1 recombinant protein, 1 vaccine, 1 immunotherapy, 1 radiopharmaceutical, 1 antisense oligonucleotide, 3 RNA therapies 1 herbal medicine…
Shots:
In the August Edition of the Know Your Investor series, we bring a condensed yet illuminating report on Arch Venture Partners
In 2023, Arch Ventures Partners participated in 6 investment rounds and added 27 companies focusing on biopharma and manufacturing & services to its portfolio
For a detailed report on all the investments, reach…
Shots:
Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers
Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma
The study reveals that four out of the ten patients received only…
In August and September, PharmaShots is all set to explore Animal Health. A topic as diverse as Animal health requires at least two months to navigate the nuanced aspects of the industry. So, we decided to split the animal health segment into two: for August, we are exploring Companion Animals, and for the subsequent month,…
Shots:
The EMA granted Positive Opinion to 2 Biologics and 5 New Chemical Entities in July 2024, leading to treatments for patients and advances in the healthcare industry
The major highlighted drugs were Johnson & Johnson’s Yuvanci to treat Pulmonary Arterial Hypertension (PAH) and Astellas’ Vyloy + CT for Gastric & Gastroesophageal Junction Cancer
PharmaShots has compiled a list…

